Evidence map›Paper›PMID 31732567›Full record

ArticleNeurology2020

Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.

Kyla A McKay, Olivia Ernstsson, Ali Manouchehrinia, Tomas Olsson, Jan Hillert

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04979546 (Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04979546 nacompletednot on this mapstarted 2021, after this paper: background citation

Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial

TypeinterventionalSponsorUniversity of AlbertaRan2021 to 2024Enrolled237ConditionsMultiple Sclerosis, Anxiety, Depression, Patient SatisfactionArmsIntensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist, Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist
3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Observational
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Quality of Life in Multiple Sclerosis.Pediatric neurology briefs · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Kyla A McKayFrom the Departments of Clinical Neuroscience (K.A.M., A.M., T.O., J.H.) and Learning, Informatics, Management and Ethics (O.E.), Karolinska Institutet; and Centre for Molecular Medicine (K.A.M., A.M., T.O.), Karolinska University Hospital, Stockholm, Sweden. kyla.mckay@ki.se.
Olivia ErnstssonFrom the Departments of Clinical Neuroscience (K.A.M., A.M., T.O., J.H.) and Learning, Informatics, Management and Ethics (O.E.), Karolinska Institutet; and Centre for Molecular Medicine (K.A.M., A.M., T.O.), Karolinska University Hospital, Stockholm, Sweden.
Ali ManouchehriniaFrom the Departments of Clinical Neuroscience (K.A.M., A.M., T.O., J.H.) and Learning, Informatics, Management and Ethics (O.E.), Karolinska Institutet; and Centre for Molecular Medicine (K.A.M., A.M., T.O.), Karolinska University Hospital, Stockholm, Sweden.
Tomas OlssonFrom the Departments of Clinical Neuroscience (K.A.M., A.M., T.O., J.H.) and Learning, Informatics, Management and Ethics (O.E.), Karolinska Institutet; and Centre for Molecular Medicine (K.A.M., A.M., T.O.), Karolinska University Hospital, Stockholm, Sweden.
Jan HillertFrom the Departments of Clinical Neuroscience (K.A.M., A.M., T.O., J.H.) and Learning, Informatics, Management and Ethics (O.E.), Karolinska Institutet; and Centre for Molecular Medicine (K.A.M., A.M., T.O.), Karolinska University Hospital, Stockholm, Sweden.

Funding

CIHR
6 · The paper itself

Abstract

objectiveTo evaluate quality of life (QoL), measured by the EQ-5D, in adults with pediatric-onset multiple sclerosis (POMS) or adult-onset multiple sclerosis (AOMS) and explore determinants of QoL in both groups.

methodsData were collected from the nationwide Swedish multiple sclerosis (MS) registry. Demographic characteristics, EQ-5D-3 level, Multiple Sclerosis Impact Scale (MSIS-29) score, Expanded Disability Status Scale (EDSS) score, Symbol Digit Modalities Test score, relapses, and disease-modifying therapy (DMT) exposure were collected on an approximately annual basis (2011-2019). Patients with definite MS with ≥2 EQ-5D measurements collected between ages 18 and 50 were included. The principal outcome was the EQ-5D visual analogue scale (EQ-VAS) score. Linear mixed models compared all available EQ-VAS scores between patients with POMS and patients with AOMS and determinants of EQ-VAS among patients with POMS and patients with AOMS (assessed separately).

resultsA total of 5,094 persons met inclusion criteria: 354 (6.9%) had POMS. A total of 21,357 unique EQ-5D scores were recorded. Most participants were female (70.0%) with a relapsing-onset disease course (98.1%). There was no difference in EQ-VAS scores between patients with POMS and patients with AOMS following adjustment for confounders (β-coefficient for patients with POMS vs patients with AOMS [reference]: 0.99; 95% confidence interval -0.89 to 2.87). Experiencing a relapse, severe neurologic disability (EDSS ≥6.0 vs <3.0), and higher MSIS-29 psychological score were consistently associated with lower QoL, while higher information processing efficiency and exposure to first-line DMTs were associated with higher QoL scores in both groups.

conclusionsThere were no differences in QoL between patients with POMS and patients with AOMS in adulthood. Findings provide support for a focus on reducing neurologic disability and improving psychological status as approaches to potentially improve the QoL of persons with MS.

Indexed as

Age of OnsetQuality of LifeAdolescentAdultDisability EvaluationFemaleHumansMaleMultiple SclerosisRegistriesSwedenYoung Adult

Identifiers

PMID31732567
PMCPMC7238943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.